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Abstract
INTRODUCTION—There are few longitudinal studies of dementia in developing countries. We
used longitudinal data from the Maracaibo Aging Study (MAS) to accurately determine the ageand sex-specific incidence of dementia in elderly Latin Americans.
METHODS—The DSM IV-R was used to diagnose dementia, which was classified as
Alzheimer’s disease (AD), vascular dementia (VaD), or other. Age- and sex-specific incidence was
estimated as the number of new cases of dementia divided by person-years of follow-up (p-y).
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RESULTS—The incidence of all dementia diagnoses was 9.10 per 1000 p-y (95% CI 7.13–11.44;
8026 total p-y), 5.18 for AD (95% CI 3.72–7.03; 7916 total p-y), and 3.35 for VaD (95% CI 2.19–
4.91; 7757 total p-y).
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DISCUSSION—Among MAS participants under 65 years of age, the incidence of dementia was
higher than that of US whites. Among individuals over 65 years of age, the incidence was
comparable to the mean of previous incidence estimates for other populations worldwide.
Keywords
Alzheimer’s disease; Epidemiology; Vascular dementia; Population-based; Hispanics

1. INTRODUCTION

Author Manuscript

The prevalence of dementia, a condition that disproportionately affects the elderly, is higher
in most Latin American countries than in developed countries [1–3]. In 2015, approximately
70.9 million Latin Americans were over 60 years of age. By 2030, that number will exceed
121 million [4]. As such, the aging of the population puts an increasing number of
individuals at risk. However, because prevalence reflects both the incidence and duration of
disease, it is a limited measure of risk.
Incidence, the rate of occurrence of new cases, is a more useful measure of risk that is
essential for evaluating temporal trends and for assessing the effects of preventative
measures. The World Health Organization′s estimates of the incidence of dementia in
developed countries ranged from 3.4 per 1000 person-years (p-y) at age 60–64 years to 99.4
per 1000 p-y at >95 years [3]. There are only nine reports on the incidence of dementia in
developing countries [5–12], all among those older than 65 years, and ranging from 3.2 per
1000 p-y in India [11] to 21.85 per 1000 p-y in Nigeria [7]. None of these studies included
complete neuropsychological and clinical assessments of all participants.
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The goal of the present study is to provide an accurate estimate of dementia incidence in
Venezuela, a developing country. Longitudinal data from the Maracaibo Aging Study (MAS)
[13] were used to determine the age- and sex-specific incidence of dementia and its
subtypes, Alzheimer’s disease (AD) and vascular dementia (VaD).

2. METHODS
2.1 Sample

Author Manuscript

The MAS is a population-based study of community-dwelling individuals aged 55 years and
older who resided in downtown Maracaibo, Santa Lucia County, Venezuela, between
January and August 1998 [14]. The MAS investigated cognitive, cardiovascular, nutritional,
and social changes associated with aging, with a special emphasis on memory-related
disorders. The baseline assessment was conducted between September 1998 and December
2001. A total of 2453 out of 3765 residents ≥55 years of age underwent a standardized,
multidimensional assessment of laboratory tests and their neuropsychological,
neuropsychiatric, cardiovascular, and nutritional status. Of the 2453 assessed at the baseline
evaluation, 198 participants were diagnosed as having dementia, and one participant was not
assigned a Clinical Dementia Rating (CDR) [15]. Of the remaining 2254 assessed patients
who composed the at-risk population, 411 (19.74%) died or relocated before the second
evaluation, 28 (1.24%) were not available for any of the three reevaluation visits, and 122
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(5.12%) declined to participate in the second evaluation. The 1693 participants who were
reexamined at least once between 2001 and 2009 composed the sample for our study (Figure
1).
The MAS was approved by the Institutional Review Board of the Cardiovascular Center at
the University of Zulia in Maracaibo. Informed consent was obtained from each participant,
or from a surrogate when appropriate, after they were provided with a complete explanation
of the study.
2.2 Dementia Assessments and Diagnoses

Author Manuscript

The assessment and diagnostic procedures of the MAS have been previously described in
detail [13]. Briefly, a social worker visited the home of each participant and conducted a
family interview. Two social workers were available during the study period, both of whom
received the same training, which consisted of practice interviews, roleplaying, visits to
Santa Lucía with various members of the team (psychologists, physicians, historian) to
understand the geography and history of the area, and biweekly feedback meetings. An
informant (usually a spouse or adult child residing in the same home as the participant) was
identified as knowledgeable about the participant’s daily activities and health issues.
Information regarding changes in the abilities of the participant was collected using an
adapted version of the Dementia Questionnaire [16], the third part of the Blessed Dementia
Scale [17], and the Self-Maintaining and Instrumental Activities of Daily Living Scale [18],
as well as information on the family history of dementia. All the participants were invited to
undergo an in-depth neuropsychiatric evaluation (performed by a trained neurologist,
psychiatrist, or internist), neuropsychological testing (by a psychologist), routine laboratory
tests, and apolipoprotein E (APOE) genotyping [19, 20].
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The neuropsychiatric assessment included a neurological examination, original and modified
versions of the Mini-Mental State Examination (MMSE) [21, 22], the Blessed OrientationMemory and Concentration Test [17], the Schwab and England Scale to assess activities of
daily living [23], the Zung Depression Scale [24], and the Neuropsychiatric Inventory [25].
The neuropsychological assessment included 17 tests for memory, abstract reasoning,
orientation, constructional ability, language, and attention [22]: the Selective Reminding Test
[26]; the Benton Visual Retention Test [27]; similarities from Wechsler Adult Intelligence
Scale-Revised [28]; identities and oddities from Mattis [29]; five items from the Rosen
Drawing Test [30]; the Boston Naming Test [31]; the Benton Multilingual Aphasia
Examination [32]; comprehension and repetition from the Boston Diagnostic Aphasia
Examination [31]; and cancellation (TMX and shapes).

Author Manuscript

Results of the neuropsychological tests were used as complementary information; diagnoses
were not based on cutoff scores. The assessments were conducted on two consecutive
mornings, usually at the Cardiovascular Center of the University of Zulia. If the participant
could not leave their home, the assessment took place at the their residence.
Diagnoses of dementia were made by consensus during a conference of physicians,
psychologists, and social workers, who discussed all ancillary information and followed the
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diagnostic strategy developed for the Washington Heights-Inwood Columbia Aging Project
in New York [22]. Subjects were classified as having dementia if they obtained a rating of
Category 1 or higher on the CDR scale [15], and they had cognitive impairment resulting in
a functional decline in their social or occupational activities from their previous level of
functioning not explained by other conditions. Baseline and incident dementia diagnoses
were classified as AD, VaD, or other dementia, based on standardized criteria for each
illness in the Diagnostic and Statistical Manual of Mental Disorders (4th Edition) [33] and
specific criteria for each dementia subtype [34–40]. Brain magnetic resonance scans
(Phillips 1.5 T) were offered to all individuals with CDR 0.5 or higher, and to a randomly
selected individuals for a total of 400 imaging studies. When available, neuroimages were
included in the discussion, and they were mostly used for differential diagnosis. Dementia
onset was estimated as the age at which the individual met the criteria for dementia, based
on a systematic review of the chronological history of cognitive and functional changes. The
consensus panel was blind to APOE genotype, previous CDR, and dementia type.
2.3 Data Analysis

Author Manuscript

The at-risk population consisted of MAS participants who were not diagnosed with
dementia during the baseline assessment. For each participant, p-y was calculated as the
number of years from baseline until (1) the time of dementia onset or (2) the time of
completion of the last assessment at which the individual was found not to have dementia,
whether they subsequently remained in the cohort, dropped out, or died. Incidence per 1000
p-y was estimated as the number of new cases of dementia, divided by the at-risk p-y,
multiplied by 1000 [41]. Confidence intervals (CIs) were calculated assuming a Poisson
distribution for the number of cases within each age interval. Incidences were standardized
using the Venezuelan population based on the 2001 national census [42] and the WHO
world population data [43].
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We added competing risk analyses suggested by the reviewer. In the methods section we
added: “Because factors leading to nonparticipation could be linked to the same factors that
affect dementia incidence [44], we conducted two types of analyses to assess the influence
of dropouts (due to death, relocation, refusal or other cause of non participation) having
developed dementia if they have stayed in the study. First, a sensitivity analysis was
conducted that assumed that dementia incidence in nonparticipants was the same, 50%,
100%, or 200% higher than the incidence in the assessed cohort. The second approach
consisted of adjustment of incidence for competing risk due to death using a proportional
subdistribution hazards model developed by Fine and Gray[45] and modified by Chang et al.
[46]. Briefly, a propensity model was developed using a logistic regression model with
covariates (age, sex, and education) assigning each individual a propensity score that
reflected his/her estimated probability of developing dementia, have all they been assessed
for dementia an additional time after baseline. Based on the median of the propensity score
of those that actually developed dementia a cutpoint was established. If the propensity score
of participants who died without developing dementia were above the cutpoint, they were
reclassified as an event and incidence of dementia recalculated.
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We fitted three types of regression models to estimate the effect of age, education, sex
(female) and APOE-ε4 genotype on the incidence of dementia (all causes, AD and VaD).
First, Cox proportional hazard regression models[47], in which participants who survived
and remained dementia-free, as well as those who died without developing dementia, were
treated as censored. Second, the modified Fine and Grey (FG) competing risks regression
models that focus on cumulative incidence[45] were generated using the command stcrreg in
STATA. Third, the FG models were generated after reclassification of individuals, i.e.
participants who remained alive and dementia-free were again treated as censored, but those
who died without developing dementia were treated either as competing risks (if their
propensity scores were above the cutpoint) or as censored (if their propensity scores were
below the cutpoint).”
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Mean values of population parameters (± SD) were compared using the Mann-Whitney rank
sum test, and p values ≤.05 were considered to be statistically significant. Statistical analyses
were performed with Epi-Info 6.04b and SPSS version 23.0, 2016.

3. RESULTS

Author Manuscript

The mean age at baseline for study participants with longitudinal data was 66.3 years of age,
and 69.5% of the study participants were women (Table 1). The study participants had, on
average, 6 years of education and their mean MMSE was 23.7. The average number of
follow-up visits by participants was 2.4 (range 2–5), and the time between the baseline and
last assessments averaged 3.45 ± 3.05 years (Table 2). The mean age at first diagnosis of
incident dementia was 75.1 ± 8.11 years. Table 1 provides statistics for individuals who did
not participate in any follow-up evaluation due to death, relocation, refusal, or other cause.
They were slightly older than those who did participate and included a smaller proportion of
women. The nonparticipant group did not differ from participants with respect to years of
education, APOE-ε4 genotype, or mean MMSE score obtained during the baseline
evaluation.
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Incidence of all dementia diagnoses was 9 cases per 1000 p-y for participants ≥55 years, and
16 cases per 1000 p-y for participants ≥65 years. The incidence of dementia increased
exponentially with age, reaching 91 cases per 1000 p-y for individuals 85 years or older
(Table 3, Figure 2). The incidence of AD and VaD also increased with age (Table 3). AD
accounted for 56% and VaD for 36% of all incident dementia cases with marginal cases of
frontotemporal dementia, Lewy body disease, Parkinson’s with dementia, and dementia
related to alcoholism. The incidence of all dementias, AD, and VaD was similar for men and
women. The incidence of all dementias and AD was higher among APOE-ε4 carriers than
noncarriers, but the presence of an APOE-e4 allele did not affect the incidence of VaD
(Table 4).
In the sensitivity analyses, the age-specific incidence of dementia was recalculated to
include nonparticipants, assuming that the nonparticipants had 1.5 to 5 times greater
incidence of dementia than participants (Table A.1). As expected, the recalculated incidence
was higher, particularly in the older groups, than when nonparticipants and participants were
assumed to have the same incidence of dementia. When incidence was calculated using the
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modified FG competing risks regression models, incidence was substantially higher than the
unadjusted models (Table A.1), particularly in the older groups.
Results of the Cox models indicated that being older, female or a carrier of at least one
APOE-ε 4 allele was associated with an increased incidence of dementia of all causes (Table
A.2). However, only age and APOE-ε4 status were significant risk factors for AD, and only
age was a risk factor for VaD. In undjusted models, low education level was not a significant
risk factor for all dementias, AD, or VaD. After adjusting for death as competing risk, results
were not radically changed, except for education, that became marginally significant for allcause dementia and VaD, but not for AD, and sex which became significant for the three
dementia groups.

4. DISCUSSION
Author Manuscript
Author Manuscript

The MAS previously reported a high prevalence of dementia in the elderly population of
Santa Lucia compared with other population-based studies in Latin America.[2] However, it
was uncertain whether the high prevalence reflected a high incidence of dementia. We
conducted an extensive follow-up evaluation of each participant by experienced local
clinicians, using standardized full neuropsychological testing, neurological examination, and
a multimodal examination of decline in activities of daily living. The results of the present
longitudinal study confirm that age at onset of dementia is somewhat earlier than in US
Whites [48] as evident by the relatively high incidence of dementia among MAS participants
who are younger than 65 years of age. However, the incidence of dementia in those older
than 65 years of age was comparable to other population-based data from other studies.[5–
10, 12] When adjusting for death as a competing risk for dementia, using a relative
conservative approach, the resulting incidence per age group have not precedents. This
finding suggests that dementia and death shared common risk factors, and once the
development of public health sector and of medical science allows decreasing mortality
rates, the magnitude of dementia rates could be much higher.
Consistent with the prevalence data, AD was the most frequent type of incident dementia.
As expected, age, sex and APOE-ε4 were important risk factors for dementia. The average
years of education was six years, which is consistent with the average years of schooling of
adults in the Venezuela [49] for that age range, and was associated to dementia only when
competing risks were considered. The mild significant association with education level
could be due to the overall low level of education of the cohort.

Author Manuscript

The present study has several limitations. The primary limitation is that incidence rates were
derived from a geographically restricted area and are not necessarily representative of all
Venezuelans or Latin Americans. Moreover, our dementia diagnoses rely on extensive
clinical evaluation but have not been autopsy confirmed by neuropathological evaluation.
Thus, we may have underestimated subtypes of dementia, such as VaD and others. Unlike
other community-based studies of dementia in developing countries, however, we were able
to verify VaD using neuroimaging data because 67% of cases of dementia had
neuroimaging. The high incidence of dementia might reflect anticipation of onset, more
severe manifestation during early stages, or highly sensitive diagnoses. None of these

Alzheimers Dement. Author manuscript; available in PMC 2019 February 01.

Maestre et al.

Page 7

Author Manuscript
Author Manuscript

possibilities can be excluded in the present study. The Santa Lucia population lives in poor
conditions relative to other populations in developed countries, including limited access to
health care, which leads to high rates of uncontrolled co-morbidities such as systemic
hypertension and diabetes. When compared with incidence rates among Caribbean
Hispanics residing in northern Manhattan, the incidence of AD in the Santa Lucia cohort
was higher (3.8% vs. 6.9% per 1000 p-y, respectively). Because both studies used similar
diagnostic procedures and analytical methods, the possibility that there is a risk factor for
AD specific to the MAS population cannot be ruled out.[50] However, most of the
Caribbean Hispanics in the US study were from the Dominican Republic and Puerto Rico;
few were from Venezuela. Finally, results of the sensitivity analysis indicate that the
estimated incidence would have been higher if dementia-related incapacity, relocation, or
death accounted for a significant proportion of nonparticipants, and modeling death as a
competing risk of dementia revealed that the overall dementia rate could be twice as the
unadjusted.
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On the other hand, the present study has many strengths. This community-based study is as
representative as possible of the population in the region, because all residents 55 years or
older were invited to participate and the participation rate at baseline was higher than 75%.
[13] The nonparticipation rate in follow-ups, excluding death and relocation, was
approximately 5%; thus, the probability that self-selection influenced the estimates of
incidence is low. We used validated questionnaires and detailed neuropsychological
instruments that provided extensive, in-depth clinical phenotyping. The diagnostic strategy
and most of the health professionals involved in assessments were the same for the baseline
and follow-up studies, thus minimizing assessment bias. The health professionals involved
in the MAS diagnostic process included a psychiatrist, a geriatrician, and usually also a
neurologist, all with specific training, expertise, and experience in dementia. Although
‘diagnostic drift’ (the tendency to expand the parameters of a diagnosis leading to more
diagnoses) cannot be excluded, cognitive performance cutoffs were established giving
careful consideration to education level to minimize the possibility that the tests penalized
individuals with lower education level and to ensure that the same diagnostic criteria were
applied. The noted association between the APOE-ε4 genotype and the incidence of AD, but
not VaD, further validates our results.
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The present study provides the first estimates of the incidence of dementia, AD, and VaD for
a population in the developing world that was not subject to a screening phase prior to
assessment, and in which diagnoses were not paradigm-based, but the result of clinical
consensus. The incidence of dementia, AD, and VaD in participants older than 65 years
reported herein are comparable to the range of estimates previously reported for both
developed [44, 51, 52] and developing [8–10, 12] countries (Figure 2). The incidence among
those 55–64 years of age is quite high compared with studies in the developed world [48],
and there is only one other reported study in the developing world for this age group, which
took place in India and which also found lower rates than MAS.[5] However, direct
comparisons to previous estimates of dementia incidence are difficult due to differences in
the diagnostic methods, the age structure of the samples, and the use of different age strata in
the analyses. We did not preselect individuals to be evaluated in depth by expert clinicians,
to undergo extensive neuropsychological assessment, or for all participants to undergo
Alzheimers Dement. Author manuscript; available in PMC 2019 February 01.
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laboratory tests. Previous incidence studies of dementia in the developing world have
carefully validated their methods, diagnostic strategies. We are building on their insight of
the difficulties of carrying out this studies in low-resource settings, not only presenting data
of Venezuela but also adding some methodological features. All previous incidence studies
in the developing world [5–12] applied a screening phase to select those individuals who
were more likely to be diagnosed as having dementia. Some used laboratory tests to evaluate
physical health,[5, 9, 11] three obtained information on daily living activities from the
participant and a proxy [7–10] and two included magnetic resonance imaging of the brain.[5,
11] Only other study reported using a consensus conference of multidisciplinary health
professionals to reach a diagnosis for all participants.[9]
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The incidence rates reported herein would have been even higher if participants with a CDR
of 0.5 were counted as having dementia and if competing risk analyses account for those
individuals that die before a diagnosis of dementia is actually recorded in the study.. Thus,
methodology can have a significant effect on estimates of incidence, and the wide range of
incidence estimates in previous studies might reflect differences in methodology as much as
actual differences in the incidence of dementia.

Author Manuscript

In summary, an accurate estimated incidence of dementia in the population of Maracaibo,
Venezuela, showed fairly high rates in those younger than 65 years, and rates comparable to
previous estimates in those older than 65 years for other countries. The wide range among
previous estimates might be at least partly attributable to variation in methodology. Although
the incidence of dementia was highest among the most elderly MAS participants, the impact
is more important for relatively young individuals (55–64 years) who contribute to the
economic support of their families, which are typically multigenerational and poor.
Although AD had the highest incidence of the subtypes of dementia, VaD also had a
relatively high incidence. Unlike AD, VaD currently offers significant opportunities for
prevention. Although extrapolation to other Latin American countries or to Hispanic
populations living in developed countries is not straightforward, the relatively high incidence
of dementia reported here is of concern, especially given life expectancy in these developing
countries has been increasing significantly. The burden on the health care system is likely to
be notable when health care resources are limited.
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RESEARCH IN CONTEXT
1. Systematic review
We reviewed the literature using PubMed and reference lists from relevant articles.
Studies of incidence of dementia in developing countries and in particular, in Latin
America are scarce. We identified several publications on subjects older than 65 y, but
none among younger than 65 and residing in a Latin American country.
2. Interpretation

Author Manuscript

Studies have shown that overall prevalence of dementia in Latin Americas as high as in
developed countries. We extend research of epidemiology of dementia by including a
population-based incidence study and including individuals 55 y or older. We found that
compared with Whites in the US, this Latin American population has high incidence in
55 – 64 age group, and intermediate incidence in older than 65y.
3. Future directions
As incidence of dementia is higher than expected in the relatively young segment of this
Hispanic population, uncovering the risk factors and understanding the mechanisms for
the higher risk of dementia is important. The possibility that the reported higher
incidence is not only limited to this population of Venezuelans, but is also the case for
Hispanics living in their country of origin or in other countries warrant extending
epidemiological studies in Hispanics to a minimum of 55 years of age.
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Figure 1.

Flow diagram showing numbers and percentages of Maracaibo Aging Study (MAS)
participants included in the baseline and follow-up assessments and incidence estimates.
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Figure 2.

Incidence of dementia vs. mean age reported herein for the Maracaibo Aging Study (MAS,
Venezuela) and for comparison purposes, in six previous studies: Brazil = Catanduva, Brazil
Study [9]; China = Anhui Cohort Study [6]; EURODEM = European Studies of Dementia
(Denmark, France, Netherlands, United Kingdom) [52]; Latin America 10/66 (Dominican
Republic, Peru, Venezuela) [10]; Mexico = Mexican Health and Aging Study [8]; and
Rochester = Rochester, MN, Study (USA).[48]
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130(56.0)
5.52±4.51
43(18.1)
21.5±11.2
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Years of formal education, y, mean ± SD
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MMSE score, mean ± SD
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All n=561
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311 (21.0)

5.87±4.11

1177.(69.5)

66.3±8.25

p indicates the significance of the difference between subjects with only the baseline assessment and those with ≥1 follow-up assessment.

Abbreviations: APOE-ε4 = Allele ε4 of the Apolipoprotein E; MMSE = Mini Mental State Examination (18); SD = standard deviation.
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Relocated n=179
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Subjects with only baseline assessment

Age at baseline, y ± SD

N= 2254

Demographic characteristics (mean±SD) of participants in the baseline and follow-up assessments of the Maracaibo Aging Study.
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Table 2
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Characteristics of participants in the Maracaibo Aging Study.
Non-Demented
CDR<1
n=1620

Demented
CDR≥1
n=73

Mean baseline age, y ± SD

65.6±7.89

Mean last follow-up age, y ± SD

70.5±8.39

Women, n (%)

All

p value

75.1±8.11

66.3±8.25

<.001

82.6±6.44

70.96±8.60

<.001

1127 (69.6)

50 (68.4)

1177 (69.5)

<.86

Years of formal Education ± SD

6.17±4.07

4.08 ± 3.69

5.87±4.11

<.001

Baseline MMSE score ± SD

23.9±4.00

19.4±4.71

23.65±4.19

<.001

Last MMSE score ± SD

23.4+4.24

14.0+5.59

23.08±4.62

<.001

APOE-ε4, % (3/4+4/4+2/4)

291(18.0)

20 (27.4)

311 (21.04)

0.02

Duration of follow-up, y ± SD

4.74±2.56

5.49±3.26

4.78±2.60

<.001

Author Manuscript

Abbreviations: APOE-ε4 = Allele ε4 of the Apolipoprotein E; MMSE = Mini Mental State Examination (18); CDR = Clinical Dementia Rating
Scale (30); SD = standard deviation.

p indicates the difference between subjects by dementia status.
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Author Manuscript

Incidence of all dementia diagnoses, Alzheimer’s disease, and vascular dementia for different age groups of
the Maracaibo Aging Study population.
Age group

Cases

Person-Years

Incidence/1000 p-y (95% CI)

55–64

6

3796

1.58 (0.58–3.44)

65–74

33

3014

10.95 (7.54–15.4)

75–84

22

1084

20.30 (12.7–30.7)

85+

12

132

90.90 (47.0–159)

All ages

73

8026

9.10 (7.13–11.4)

Women, all ages

50

5699

8.77 (6.51–11.6)

Men, all ages

23

2328

9.88 (6.26–14.8)

≥ 60

71

5885

12.06

≥ 65

67

4230

15.84

Dementia

Author Manuscript

11.531

Standardized incidence

10.722
Alzheimer’s disease

Author Manuscript

55–64

3

3784

0.79 (0.16–2.32)

65–74

19

2962

6.42 (3.86–10.02)

75–84

12

1055

11.37 (5.88–19.87)

85+

7

115

60.87 (24.47–125.41)

All ages

41

7916

5.18 (3.72–7.03)

Women, all ages

29

5618

5.16 (3.46–7.41)

Men, all ages

12

2298

5.22 (2.7–9.12)

≥ 60

39

5775

6.75

≥ 65

38

4132

9.20
6.971
6.422

Standardized incidence

Vascular dementia

Author Manuscript

55–64

3

3772

0.8 (0.16–2.32)

65–74

11

2875

3.83 (1.91–6.85)

75–84

9

1012

8.89 (4.07–16.88)

85+

3

98

30.61 (6.31–89.46)

All ages

26

7757

3.35 (2.19–4.91)

Women, all ages

17

5495

3.09 (1.8–4.95)

Men, all ages

9

2262

3.98(1.82–7.55)

≥ 60

26

5631

4.62

≥ 65

23

3985

5.77

Standardized incidence

4.361
4.092

Abbreviations: p-y = person-years; CI = confidence intervals.

1

Age-standardized incidence based on the age structure of the Venezuelan population [42].
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2

Age-standardized incidence based on the age structure of the world population [43].
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Table 4
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Incidence of all dementia diagnoses, Alzheimer’s disease, and vascular dementia for carriers and non-carriers
of the APOE-ε4 allele.
APOE-e4 status

Cases

Person-Years

Incidence/1000 p-y (95% CI)

Dementia
Carrier of APOE-ε4

20

1477

13.50 (8.27–20.9)

Non-carrier of APOE-ε4

51

5658

9.01 (6.70–11.8)

Carrier of APOE-ε4

13

1448

8.98 (4.78–15.4)

Non-carrier of APOE-ε4

27

5581

4.84 (3.19–7.04)

Carrier of APOE-ε4

5

1373

3.64 (1.18–8.50)

Non-carrier of APOE-ε4

20

5494

3.64 (2.22–5.62)

Alzheimer’s disease

Vascular dementia
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Abbreviations: APOE-ε4 = Allele ε4 of the Apolipoprotein E; p-y = person-years; CI = confidence intervals.
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